Business
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and ankylosing spondylitits (AS). BIMZELX, a dual inhibitor of IL-17A and IL-17F,1 demonstrated sustained control of inflammat
About this update from Ucb S.a.
[{"type":"list","items":[{"val":[{"type":"text","content":"Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients with psoriatic arthritis (PsA) naïve to biologics or who had an inadequate response to, or were intolerant of, tumor necrosis factor inhibitors, respectively†*","length":331,"tagName":"p"}]},{"val":[{"type":"text","content":"Lasting improvements in physical function across the full spectrum of patients with axial spondyloarthritis: ASAS40, a composite endpoint, was sustained at three years by 60.4% and 60.1% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS), respectively¥*","length":308,"tagName":"p"}]},{"val":[{"type":"text","content":"Long-term inflammation control through three years: New data demonstrated consistent sustainability of efficacy across stringent clinical endpoints in PsA, nr-axSpA, and AS, showing potential to improve long-term outcomes and prevent structural damage","length":256,"tagName":"p"}]},{"val":[{"type":"text","content":"Dual inhibition: BIMZELX® is the first and only approved medicine designed to selectively inhibit interleukin 17A (IL-17A) in addition to interleukin 17F (IL-17F)","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1057,"olType":false},{"type":"text","content":"ATLANTA, June 11, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with active psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), which includes both non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and ankylosing spondylitits (AS). BIMZELX, a dual inhibitor of IL-17A and IL-17F,1 demonstrated sustained control of inflammation and deep efficacy in patients living with PsA and axSpA,2-5 chronic inflammatory diseases with considerable impact on physical and emotional wellbeing.6-7","length":713,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/UCB, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/UCB, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https:/...